Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...

(Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent ...

Boston Children's Hospital and Harvard Medical School researchers have discovered a neuroimmune communication pathway that ...

In a new study, numerous genomic regions potentially affecting the structure of the discs and inflammatory factors were found ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

Lumbar disk herniation is one of the most common structural changes in the lower back and the most common cause of radiating ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...

Gracie, a young woman from East Yorkshire, faced a harrowing ordeal when she was diagnosed with a debilitating condition that causes sudden, severe, electric shock-like pain in parts of the face. The ...